KYONGBO PHARMACEUTICAL CO., LTD.
Financials
Valuation Metrics
KYONGBO PHARMACEUTICAL CO., LTD.'s Market Cap is ₩1229B. At end of 2025 it was ₩1379B. Ranked #1090 of 2,405 in KR market (top 45%), #526 of 778 on KOSPI (top 68%), #127 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 122.88B KRW | KR#1,090/2,405 Sec#127/231 |
| Revenue | 279.55B KRW | KR#858/2,405 Sec#40/231 |
| Net Income | 5.06B KRW | KR#1,206/2,405 Sec#79/231 |
| Total Assets | 367.57B KRW | KR#917/2,405 Sec#57/231 |
| Net Assets | 146.99B KRW | KR#1,150/2,405 Sec#82/231 |
| Employees | 525 | KR#475/2,405 Sec#39/231 |
| Value | ||
| P/E | 24.31x | KR#1,270/2,405 Sec#77/231 |
| P/B | 0.84x | KR#1,373/2,405 Sec#86/231 |
| PEG | 0.02x | KR#201/2,405 Sec#9/231 |
| P/S | 0.44x | KR#884/2,405 Sec#39/231 |
| EV/EBITDA | 103.07x | KR#1,496/2,405 Sec#99/231 |
| FCF Yield | -27.74% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | 3.44% | KR#1,293/2,405 Sec#89/231 |
| ROA | 1.38% | KR#1,337/2,405 Sec#95/231 |
| Op. Margin | 0.94% | KR#1,502/2,405 Sec#105/231 |
| Revenue Growth | 14.83% | KR#691/2,405 Sec#67/231 |
| Earnings Growth | 1151.09% | KR#56/2,405 Sec#5/231 |
| Financial Health | ||
| Debt Ratio | 150.06% | KR#1,890/2,405 Sec#208/231 |
| Total Debt | 155.44B KRW | KR#595/2,405 Sec#33/231 |
| FCF | -34.08B KRW | KR#2,003/2,405 Sec#195/231 |
| Cash | 6.92B KRW | KR#1,880/2,405 Sec#169/231 |
| Current Ratio | 0.88x | KR#1,850/2,405 Sec#181/231 |
| Net Debt/EBITDA | 56.40x | KR#1,489/2,405 Sec#104/231 |
| Dividend | ||
| Div. Yield | 0.97% | KR#1,145/2,405 Sec#66/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -12.88% | KR#953/2,405 Sec#58/231 |
| 1M Return | -5.17% | KR#723/2,405 Sec#72/231 |
| From 52W High | -44.73% | KR#939/2,405 Sec#63/231 |
| 1Y MDD | -42.16% | KR#645/2,405 Sec#44/231 |
| Trading | ||
| Volume | 5,918 shares | KR#2,047/2,405 Sec#205/231 |
| Trading Value | 30.4M KRW | KR#1,954/2,405 Sec#204/231 |
| Foreign Own. | 2.25% | KR#1,538/2,405 Sec#146/231 |
| Per Share | ||
| EPS | 211 KRW | KR#1,265/2,405 Sec#86/231 |
| BPS | 6,148 KRW | KR#1,358/2,405 Sec#95/231 |
Company Info
Established in 1987 as a specialized Active Pharmaceutical Ingredient (API) company, the company expanded into finished pharmaceutical products in 2002 and was renamed Kyung Bo Pharm. in 2007. It markets specialized pharmaceuticals, including cardiovascular drugs and inhalant anesthetics, along with various over-the-counter drugs, while exporting cephalosporin antibiotics like Ceftriaxone domestically and internationally from its API division. Kyung Bo Pharm. is diversifying into medical devices and animal health products, such as animal pharmaceuticals and nutritional supplements. Headquartered in Asan-si, Chungcheongnam-do, the company is developing ADC (Antibody-Drug Conjugate) anticancer drug technologies for entry into the global ADC CDMO market.